Abstract:

The duration of treatment of multidrug-resistant tuberculosis (MDR-TB) is 18-24 months, and severe adverse effect, poor treatment compliance, and no second-line anti-tuberculosis drugs to form an effective treatment regimen for some patients due to the wide drug resistance spectrum and led to high mortality always happened in the treatment. Therefore, the research of new drugs for MDR-TB treatment is an important issue for global tuberculosis control, as well as the key to improve the status of MDR-TB control and prevention in China. Pretomanid (PA-824), which was developed by the TB Alliance, combined with bedaquiline and linezolid to form the BPaL regimen. The new regimen had advantages of short course, oral drugs in the whole treatment, improved treatment compliance, high cure rate, brings new hope for severe MDR-TB patients, and was recommended by World Health Organization in 2020. Currently, bedaquiline and linezolid are available in China and used as second-line anti-tuberculosis drugs for the MDR-TB treatment. Therefore, it is urgent for PA-824 to be approved in China to save more MDR-TB patients. The Chinese Antituberculosis Association and the Chinese Center for Disease Control and Prevention co-organized domestic experts on TB control, clinical and basic research to write Recommendations on pretomanid (PA-824) in the treatment of multidrug-resistant tuberculosis after discussions, to provide reference for accelerating the registration and application of PA-824 and BPaL regimen in China.

Key words: Tuberculosis, Drug resistance,multiple, Pretomanid (PA-824), Therapeutic uses, Consensus development conferences as topic